0
NantKwest, Inc. Banner Image

NantKwest, Inc.

  • Ticker NK
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
NantKwest, Inc. Logo Image
  • 51-200 Employees
  • Based in Culver City, California
NantKwest (NASDAQ: NK) is an innovative, clinical-stage immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safetyMore of these optimized, activated NK cells—as well as their activity against a broad range of cancers—has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest’s goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
NantKwest, Inc.

Most Recent Annual Report

NantKwest, Inc.
MOST RECENT 2019 Annual Report and Form 10K

Older/Archived Annual Reports